drugset / Trial / NCT01521663

Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)

NCT01521663 ↗

Phase 2 Completed 159 enrolled Impax Laboratories, LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether IPX159 is safe and effective in treating symptoms of RLS in subjects with Restless Legs Syndrome.

Timeline

Start
2011-11
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Subject IPX159 Unknown 270 mg —